| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.1 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |